ESTEVE EQUIPE 1 - HRA PHARMA

WITH SLIDEFORGE

ESTEVE - HRA PHARMA

Package: Premium

Plan start date: 03/06/2024

Plan end date: 01/06/2025
Hours saved since the beginning: 7,321 hours or 1,045 days

Actual progression :
Ended (Transfer to new Dashboard)

(Please note: Your presentation will appear in the table below on the next automatic update)

Presentation's name

number of slides

Date v1 received

Contact

Redesign Slide Marta

6

01/03/2025

Marta

Redesign Slide Marta

12

15/01/2025

Marta

ENDOCAN-COMETE

3

17/12/2024

Marta

Wang et al Endocrine Practice 2024

14

11/12/2024

Marta

Complementary Data Newsletter Dec 2024

11

09/12/2024

Myriam

Metyrapone studies

25

09/12/2024

Marta

Pass Keto Newsletter December 2024

4

09/12/2024

Myriam

Medical Plan

155

21/08/2024

Marta

DOKEOS Cushing's syndrome_Dokeos_ASF_v.2

45

13/08/2024

Marta

DOKEOS Brief Cushing's syndrome_Dokeos_ASF_v.2

31

13/08/2024

Marta

Dokeos PCV 1Z

9

09/09/2024

Marta

Slides redone during transfer

52

09/09/2024

Global

Preferred drug based on clinical situation in Cushing's syndrome 22.07.2024

2

24/07/2024

Marta

Mild Autonomous Cortisol Secretion_Dokeos_ASF_v.1

29

22/07/2024

Marta

Lysodren clinical studies training

51

22/07/2024

Marta

Dokeos Ketoconazole HRA Slide Deck July 19th 2024

5

22/07/2024

Marta

Metyrapone clinical trials training

36

22/07/2024

Marta

General-Introduction-V1

13

18/07/2024

Marta

Global-Mitotane-deck_Lysodren module-15.07. 24_ ST MZ

55

17/07/2024

Marta

HCP_Slide_Deck_Metyrapone_Differentiation Data - 2024.04.03

17

08/07/2024

Sébastien

HCP_Metyrapone_7+slides

7

04/07/2024

Marta

Dokeos Ketoconazole HRA Slide Deck

32

03/07/2024

Marta

LYSOSAFE presentation

12

27/06/2024

Marta

Circadian rhythm of cortisol & metyrapone_HCP slides deck_AS v.3

37

24/06/2024

Anna 

Pediatric adrenocortical carcinoma_HCPs slides deck_AS v.1

36

20/06/2024

Anna 

Metyrapone in the management of endogenous Cushing’s syndrome

50

14/06/2024

Marta

Ketoconazole HRA in the management 
of endogenous Cushing’s

52

14/06/2024

Marta

ACC_pathology_Deck_ST_22.05.24

47

03/06/2024

Sébastien

SLIDEFORGE

Siège social : 5 RUE PASTEUR, 92800 PUTEAUX

SAS au capital de 9000€

N° SIRET : 98462199500013/ RCS NANTERRE 984621995 / APE : 5819Z

N° TVA intracommunautaire : FR75 984621995

  • slideforge